MarketLens
Sign Up

Why Did CEL-SCI Stock Plunge After Its Latest Offering

3 months ago
SHARE THIS ON:

Why Did CEL-SCI Stock Plunge After Its Latest Offering

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News2 weeks ago

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

Silence Therapeutics priced an upsized $175M underwritten public offering of 12,962,963 ADSs at $13.50 each, after strong demand. The clinical-stage biotech could use proceeds to fund siRNA pipeline d...
Stock News1 months ago

Why CELC Stock Declined 15% in a Week Despite a Major FDA Win

Celcuity (CELC) fell 15% in a week after FDA approval of Revtorpyk, as investors focused on a late Q3 2026 launch that delays commercial sales and near-term revenues.
Stock News1 months ago

CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer

CEL-SCI will launch an FDA registration-enabling Phase 3 confirmatory study for Multikine in newly diagnosed head and neck cancer, a key step toward market approval.
Stock News1 months ago

Why FuelCell Energy Stock Is Tumbling on Wednesday

FuelCell Energy shares fell sharply Wednesday after the company announced a stock offering at a below-market price, triggering dilution concerns.

Breaking News

View All →

Top Headlines

View More →
Stock News54 minutes ago

Prediction: Nvidia's Shares Will Fall for a 5th Consecutive Quarter After Reporting Earnings on Aug. 26

Stock News1 hour ago

Alphabet Investors Are Still Underestimating Google Cloud

Stock News2 hours ago

Don't Sleep On Software

Stock News2 hours ago

Dickens: NVDA Now Full Stack AI Company, Blackwell & Vera Rubin Add Muscle

Stock News3 hours ago

NVIDIA, JPM & 2 More Stocks to Buy as Oil, Rates & AI Reshape Market